Developing enzymes to block harmful effects of certain antibodies
Engineering IgG-specific endoglycosidases to selectively defeat effector functions
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11130324
This study is exploring how to create special enzymes that can change harmful IgG antibodies in conditions like severe dengue and autoimmune diseases, with the goal of developing new treatments that help patients feel better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11130324 on ClinicalTrials.gov |
What this research studies
This research focuses on engineering specific enzymes that can target and modify IgG antibodies, which are crucial for the immune response but can also cause harmful effects in conditions like severe dengue and autoimmune diseases. By understanding how certain bacteria use these enzymes to evade the immune system, the researchers aim to create treatments that can selectively inhibit the harmful functions of these antibodies. This approach could lead to new therapies that improve patient outcomes in diseases where IgG antibodies play a detrimental role.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from autoimmune diseases or severe conditions exacerbated by IgG-mediated effects, such as severe dengue or COVID-19.
Not a fit: Patients with conditions unrelated to IgG antibody functions or those who do not have autoimmune diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that reduce the harmful effects of IgG antibodies in various diseases.
How similar studies have performed: Previous research has shown promise in using similar enzymatic approaches to modify antibody functions, indicating potential for success in this novel application.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUNDBERG, ERIC JOHN — EMORY UNIVERSITY
- Study coordinator: SUNDBERG, ERIC JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder